Destiny Pharma to Present XF-73 Nasal Gel Data at ESCMID Conference

Brighton, United Kingdom – 20 August 2024 – Destiny Pharma will present clinical data from its Phase 2b trial on XF-73 nasal gel at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) conference in Porto, Portugal. The conference, focusing on antimicrobial resistance, will take place from 17-20 September 2024.

S. aureus nasal carriage is a risk factor for bacteremia and surgical site infections in cardiac surgery. The Phase 2 trial of XF-73 showed a rapid >99% reduction in nasal S. aureus burden prior to surgery. This effect was maintained for up to six days post-surgery. Significantly fewer patients required post-operative antibiotics in the XF-73 group compared to the placebo group.

XF-73's benefits include rapid decolonisation and a low likelihood of resistance. Clinical practices may improve with better compliance and reduced antibiotic use. Destiny Pharma plans Phase 3 studies to gain regulatory approval for XF-73.